A 28-year-old woman is brought to the emergency department due to a 5-day history of extreme fatigue, easy bruising, and spontaneous gingival bleeding. She has no significant past medical history. Her temperature is 37.9°C (100.2°F), blood pressure is 105/65 mmHg, and pulse is 112/min. Physical examination reveals diffuse petechiae across her trunk and extremities, as well as oozing from a recent venipuncture site. Laboratory studies show:
| Laboratory Study | Result |
|---|---|
| Hemoglobin | 7.8 g/dL |
| Leukocytes | 34,000/mm³ |
| Platelets | 15,000/mm³ |
| Prothrombin time | 24 sec |
| Partial thromboplastin time | 50 sec |
| Fibrinogen | 90 mg/dL |
A peripheral blood smear demonstrates numerous atypical promyelocytes containing abundant azurophilic granules and multiple Auer rods.
Arrange the following steps in the most appropriate chronological sequence for the management of this patient.
- 1Initiate therapy with all-trans retinoic acid (ATRA)
- 2Obtain bone marrow aspiration and biopsy samples
- 3Confirm the presence of the t(15;17) chromosomal translocation
- 4Add comprehensive induction therapy such as arsenic trioxide
Answer
The correct sequence is to first initiate ATRA, followed by obtaining bone marrow samples, confirming the t(15;17) translocation, and finally adding comprehensive induction therapy like arsenic trioxide.
The correct management sequence for acute promyelocytic leukemia (APL) prioritizes the immediate reversal of its most fatal complication: disseminated intravascular coagulation (DIC). Upon clinical and morphologic suspicion of APL (e.g., bleeding diathesis, abnormal coagulation profile, and promyelocytes with Auer rods on peripheral smear), all-trans retinoic acid (ATRA) must be administered immediately. ATRA drives the malignant promyelocytes to differentiate into mature neutrophils, rapidly halting the release of procoagulant factors and resolving the DIC. This life-saving intervention must never be delayed for diagnostic procedures. Following the initiation of ATRA and necessary transfusion support, a bone marrow aspiration and biopsy should be performed to obtain samples for definitive testing. These samples are then analyzed using cytogenetics, FISH, or PCR to confirm the presence of the t(15;17) chromosomal translocation and the resultant PML-RARA fusion gene. Once the diagnosis is definitively confirmed and the patient's risk profile is established, comprehensive induction therapy utilizing agents such as arsenic trioxide and/or an anthracycline is added to the ATRA regimen to achieve complete remission.
Step-by-Step Solution
Key Concept
In suspected acute promyelocytic leukemia (APL), all-trans retinoic acid (ATRA) must be initiated immediately upon clinical and morphologic suspicion to prevent fatal coagulopathy, prior to obtaining definitive genetic confirmation.
Alternative Method
While some centers may obtain peripheral blood for rapid FISH prior to the formal bone marrow biopsy, empiric ATRA administration remains the absolute first step regardless of testing availability or scheduling.
Estimated Time:1m 30s